CD4 and autoimmune disease: Clearly, the characterization of the BCL2A1 interactome would help to elucidate the mechanism/s involved in the TH17 regulatory effect of BCL2A1 and to precisely identify this cell death regulator as a potential relevant target for the activation/differentiation of CD4+ cells and for the control of autoimmune diseases.